The newly nicknamed cicada covid variant has quietly re-emerged in the United States and elsewhere, detected in wastewater and nasal swabs across multiple states even as overall Covid activity remains low. Public health officials are weighing a mix of genetic red flags and modest prevalence numbers against a crowded seasonal landscape of influenza, RSV and other respiratory and gastrointestinal illnesses that produce overlapping symptoms.
Why this matters now
Health surveillance data shows the BA. 3. 2 lineage, often called cicada covid variant, carries a large number of mutations in its spike protein that experts fear could reduce protection from prior infection or vaccination. At the same time, clinical presentation in the community has become less distinctive: common signs such as sniffles, cough, muscle aches and fever mirror influenza and RSV, meaning individuals generally cannot determine which pathogen they have without testing. Masks are largely gone and uptake of the new seasonal Covid shots was low this winter, factors that shape population vulnerability even when case counts appear subdued.
Cicada Covid Variant: mutations and immunity
Genomic analyses cited in public health reports identify the BA. 3. 2 lineage as highly mutated relative to strains targeted by recent vaccines. The variant’s spike protein harbors roughly 70–75 mutations in some analyses, a scale of change experts describe as making it “very immunologically distinct compared to previous variants. ” Laboratory studies referenced in surveillance summaries found evidence the variant can evade antibodies in controlled settings, prompting continued monitoring by agencies and classification as a variant under monitoring at an international public health body.
Andrew Pekosz, Ph. D., virologist at the Johns Hopkins School of Public Health, said, “It has a lot of mutations that may cause it to look different to your immune system. ” T. Ryan Gregory, Ph. D., professor of evolutionary biology at the University of Guelph, offered the nickname that evokes the variant’s pattern of long subterranean circulation before renewed visibility.
Prevalence, surveillance and symptom confusion
Surveillance snapshots paint a mixed picture of how widespread the cicada covid variant is. National genomic data shows BA. 3. 2 was detected in wastewater or clinical samples across many states, and early sequence shares represented only a small fraction of circulating viruses in recent windows—measured at under one percent in two different reporting periods. The variant has been found in multiple countries and in travelers’ samples in genomic surveillance programs, indicating international spread but not dominance.
Because symptoms overlap among respiratory pathogens, wastewater signals and genomic sequencing are playing an outsized role in hinting which virus may be circulating locally. Jennifer Nuzzo, director of the Pandemic Center at Brown University School of Public Health, said local wastewater data can hint at prevalence, while Marlene Wolfe, assistant professor of environmental health at Emory University, emphasized that the dynamics of circulation differ by virus and by place.
Clinicians stress that the loss of distinctive early-pandemic signs—such as the once-common loss of taste and smell—means symptomatic diagnosis is unreliable. Dr. Geeta Sood, epidemiologist at Johns Hopkins Bayview Medical Center, said, “We also can’t really predict, like before, what someone has based on what is circulating. It could be Covid, it could be influenza, and now we have added the prolonged RSV to the mix. “
Regional and global ripple effects
Regional patterns already show variation: some states report moderate respiratory activity while others remain low, and RSV continues to be high in several states. The cicada covid variant’s presence in wastewater samples across many jurisdictions suggests it will continue to be tracked alongside seasonal influenza and RSV, particularly where local testing and vaccination uptake remain uneven. Public health agencies continue genomic surveillance and observational studies to evaluate vaccine and antiviral effectiveness against BA. 3. 2 in real-world settings.
Historical season totals cited in national health data underscore why vigilance matters: recent respiratory seasons produced substantial hospitalizations and deaths from Covid even when overall risk perceptions shifted, reinforcing the need to pair genetic surveillance with clinical and hospital metrics.
Given its genetic distinctiveness and the crowded field of circulating pathogens, what combination of community surveillance, targeted testing and updated vaccination strategies will best blunt any potential rise tied to the cicada covid variant?
